Roche has reported positive results from the Phase III IMpower130 study, which evaluated the efficacy and safety of Tecentriq (atezolizumab) in combination with carboplatin and nab-paclitaxel versus chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC).
The analysis showed that the Tecentriq-based combination helped people live significantly longer and reduced the risk of disease worsening or death compared to chemotherapy alone.
Go deeper with GlobalData
The Phase III, multi-centre, open-label, randomised IMpower130 study, which enrolled 723 people, evaluated the safety of the combination for chemotherapy-naïve patients with stage IV non-squamous NSCLC.
Roche chief medical officer and Global Product Development head Sandra Horning said: “Initial treatment with this Tecentriq-based combination provided a significant survival benefit for people with non-squamous non-small cell lung cancer, the most common form of lung cancer.
“Lung cancer is a complex disease and this combination could offer a new potential treatment option. We will work with global health authorities to bring this regimen to people living with this disease as soon as possible.”
People who were enrolled in Arm A received Tecentriq and carboplatin during the treatment-induction phase.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThey were given the combination on the first day and received nab-paclitaxel on days 1, 8 and 15 of each 21-day cycle for four or six cycles or until loss of clinical benefit, whichever comes first.
People in Arm B received carboplatin on the first day and nab-paclitaxel on days 1, 8 and 15 of each 21-day cycle for four or six cycles or until progression of the disease.
The study’s co-primary endpoints were progression free survival as determined by the investigator using RECIST v1.1, and overall survival in the ITT-WT population.
IMpower130 met its co-primary endpoints of OS and PFS.
Roche is currently carrying out eight Phase III lung cancer studies to evaluate Tecentriq alone or in combination with other medicines.
